Contact this trialFirst, we need to learn more about you.
Monoclonal Antibodies
Brigatinib + Bevacizumab for Lung Cancer
Recruiting1 awardPhase 1
Duarte, California
This trial tests brigatinib and bevacizumab in patients with a specific type of lung cancer that has spread or come back. Brigatinib blocks growth signals in cancer cells, while bevacizumab blocks the tumor's blood supply. The goal is to find the best dose and see how well these drugs work together.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service